2
Mississauga, On, Canada – October 24, 2020: Astrazeneca Canada company sign is seen in Mississauga, Ontario, Canada. AstraZeneca plc is a British pharmaceutical and biopharmaceutical company. | Image Credit: © JHVEPhoto – stock.adobe.com
AstraZeneca announced on May 6, 2025 that its Calquence (acalabrutinib), a second-generation, selective inhibitor of Bruton’s tyrosine kinase (BTK), was approved in the European Union in combination with bendamustine and rituximab for treatment of adults with mantle cell lymphoma (MCL) that has been previously untreated, and who are not eligible for an autologous stem cell transplant (1). Acalabrutinib had been…